###begin article-title 0
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch</italic>
###xml 19 28 19 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin </italic>
A functional Notch-survivin gene signature in basal breast cancer
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 101 106 <span type="species:ncbi:9606">human</span>
Basal-type, or triple-negative, breast cancer (lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 expression) is a high-risk disease for which no molecular therapies are currently available. We studied genetic signatures of basal breast cancer potentially suitable for therapeutic intervention.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 272 280 <span type="species:ncbi:9606">patients</span>
We analyzed protein expression of the Notch-1 intracellular domain and survivin by immunohistochemistry in a series of basal breast cancer patients. A hierarchical clustering and overall survival analysis was carried out on a microarray mRNA database of 232 breast cancer patients. Fifteen published mRNA datasets containing estrogen receptor-negative or estrogen receptor-positive samples were subjected to meta-analysis for co-segregated gene expression. Experiments of plasmid transfection and gene silencing were carried out in estrogen receptor-negative MDA-MB-231 breast cancer cells.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 160 168 160 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 268 276 268 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 426 434 426 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 438 447 438 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin </italic>
The developmental signaling regulator Notch-1 was highly expressed in breast cancer, compared with normal tissue, and was segregated with basal disease. Higher Notch-1 levels correlated with progressively abbreviated overall survival, and with increased expression of survivin, a tumor-associated cell death and mitotic regulator implicated in stem cell viability. Analysis of Pearson's correlation coefficient indicated that Notch-1 and survivin co-segregated in basal breast cancer. Notch-1 stimulation in MDA-MB-231 cells increased survivin expression, whereas silencing Notch reduced survivin levels.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 2 19 2 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1&#8211;survivin </italic>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
A Notch-1-survivin functional gene signature is a hallmark of basal breast cancer, and may contribute to disease pathogenesis. Antagonists of Notch and survivin currently in the clinic may be tested as novel molecular therapy for these recurrence-prone patients.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 402 403 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 482 483 482 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 583 584 583 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 585 586 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 650 651 650 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 733 734 733 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 882 884 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1087 1089 1087 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1227 1229 1227 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 622 633 <span type="species:ncbi:111938">gatekeepers</span>
###xml 743 751 <span type="species:ncbi:9606">patients</span>
The introduction of molecular gene signatures in breast cancer provides important prognostic and predictive information [1-3], and holds promise for individualized molecular therapy of these patients [4]. Certain subtypes of breast cancer, however, continue to pose therapeutic challenges [4]. For example, basal breast cancer is a myoepithelial disease variant characterized by high histologic grade [5], by the absence of HER-2 (ErB2) and receptors for estrogen and progesterone [6], by the expression of basal cytokeratins (that is, keratin 5) and proliferation-associated genes [7,8], as well as by defects in genomic gatekeepers, p53, or BRCA1 [9]. While immunohistochemical diagnosis of basal breast cancer is straightforward [6], these patients have limited therapeutic options: the response to mainstay chemotherapy is not uniform and is affected by the type of drugs used [10]; estrogen or HER-2 targeting is not indicated; and attempts to disable ancillary signaling pathways, for instance coordinated by the epidermal growth factor receptor, have so far shown little promise [11]. This adds to a high rate of relapses, which in several series has been linked to shortened overall survival and to death from disease [12].
###end p 11
###begin p 12
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 769 771 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 655 660 <span type="species:ncbi:9606">human</span>
Although the cell of origin of basal breast cancer has not been conclusively identified [5], a link to the progenitor/stem cell compartment of the mammary epithelium has been proposed [13]. In this context, developmental gene expression pathways that control the interplay between cell proliferation, survival, and differentiation are candidates for stem cell-derived mammary tumorigenesis [14]. One such pathway is centered on the Notch family of cell surface receptors [15] - which affects the mammary stem cell niche [16], and has been associated with malignant transformation [17] and aggressive tumor behavior [18]. Notch expression is correlated to human breast cancer formation but the downstream pathways that guide such behavior are still under investigation [19,20].
###end p 12
###begin p 13
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
Among the candidate effector molecules controlling stem cell viability is survivin, a dual regulator of cell division and apoptosis, broadly overexpressed in cancer [21]. Consistent with its onco-fetal pattern of expression, survivin is essential for tissue homeostasis [21] - and conditional knockout studies have suggested a potential critical role of this pathway in maintaining stem cell viability, at least in certain tissue compartments [22].
###end p 13
###begin p 14
In the present study, we used a combination of hierarchical clustering and overall survival analysis of a novel microarray dataset, meta-analysis of published gene profiling studies, and cell culture experiments to investigate a potential role of a Notch-1-survivin signaling axis in breast cancer.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
Immunohistochemistry
###end title 16
###begin p 17
###xml 237 244 <span type="species:ncbi:9606">patient</span>
Nine cases of basal breast cancers with associated clinical and pathological data were obtained from the archives of the Department of Pathology, University of Massachusetts Medical School. Analysis of anonymous discarded tissue with no patient identifiers was approved by and in compliance with Institutional Review Board guidelines.
###end p 17
###begin p 18
###xml 184 185 177 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 186 188 179 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 785 787 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 396 402 <span type="species:ncbi:9986">rabbit</span>
###xml 535 541 <span type="species:ncbi:9986">rabbit</span>
###xml 618 629 <span type="species:ncbi:3704">horseradish</span>
Tissue sections (5 mum) were cut from paraffin blocks, deparaffinized in xylene, rehydrated, and baked overnight at 60degreesC. Slides were quenched for endogenous peroxidase with 3% H2O2 in methanol for 20 minutes, and were processed for antigen retrieval by pressure cooking in 9 mM sodium citrate, pH 6.0, for 20 minutes. Slides were washed in PBS, and incubated overnight at 4degreesC with a rabbit antibody to the Notch-1 intracellular domain (NIC) or control IgG, were rinsed, and were further incubated with a biotinylated anti-rabbit IgG for 10 minutes at 22degreesC. After addition of streptavidin-conjugated horseradish peroxidase, the slides were incubated with 3',3'-diamino-benzidine for 3 to 10 minutes, and were counterstained with hematoxylin, as described previously [23].
###end p 18
###begin title 19
Hierarchical clustering analysis of Notch-1 mRNA expression in breast cancer
###end title 19
###begin p 20
###xml 7 9 7 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 430 438 430 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 40 45 <span type="species:ncbi:9606">human</span>
The log2 Cy5/Cy3 ratios of 232 cases of human breast cancer and their associated clinical data were downloaded from the University of North Carolina Microarray Database [24,25]. Only genes where the Lowess normalized intensity values in both channels were > 30 and data existed in > 70% samples were included for analysis. The gene set was further filtered to include only genes with Pearson's correlation coefficient > 0.58 with Notch-1 (n = 101).
###end p 20
###begin p 21
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 381 389 381 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 392 394 392 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
Two-way hierarchical clustering was performed using Cluster v3 [26], and the results were displayed using JavaTreeview [27]. Analysis of overall survival (log-rank test) was carried out using JMP 6.0 [28] (SAS Institute, Cary, NC, USA) on the subset of breast cancer patients in this cohort with available clinical data (n = 125). Data were plotted for each quartile of normalized Notch-1 log2 ratios, from highest (first quartile) to lowest (fourth quartile). The breast cancer patients were further divided into basal (n = 35) or nonbasal (n = 88) subgroups and were analyzed for overall survival (log-rank test) using JMP 6.0 [28].
###end p 21
###begin title 22
Meta-analysis of Oncomine microarray data
###end title 22
###begin p 23
###xml 22 24 22 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 25 27 25 27 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 199 207 199 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 211 220 211 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin </italic>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 423 425 423 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 618 619 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 704 711 704 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1</italic>
###xml 713 721 713 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 727 736 727 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5</italic>
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 250 257 <span type="species:ncbi:9606">patient</span>
We reviewed Oncomine [29,30] for independent human breast cancer microarray datasets comparing estrogen receptor (ER)-negative and ER-positive tumors. Databases from 15 studies were found to contain Notch-1 and survivin relative expression data. The patient characteristics and analyses performed in each study are summarized in Table 1. Descriptive statistics including the mean, standard error, and a two-tailed unpaired t test were calculated for the comparisons between ER-positive and ER-negative samples within each study. Separately for ER-negative and ER-positive samples, a Pearson's correlation coefficient (r) was calculated for each study to measure levels of pair-wise co-expression between Notch-1, survivin, and keratin-5.
###end p 23
###begin p 24
Published datasets included in the meta-analysis
###end p 24
###begin p 25
###xml 52 57 <span type="species:ncbi:9606">human</span>
Sixteen datasets derived from an unbiased search of human breast cancer microarrays on Oncomine were identified that matched the study criteria.
###end p 25
###begin p 26
###xml 32 34 32 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 67 69 67 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z </italic>
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 114 116 114 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z </italic>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 379 381 379 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z </italic>
###xml 503 505 503 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z </italic>
###xml 825 827 825 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Z </italic>
###xml 895 897 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 952 959 952 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1</italic>
###xml 961 969 961 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 975 985 975 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5 </italic>
The 95% confidence interval for r was calculated based on Fisher's Z transformation [31]. In one study a Fisher's Z transformation could not be performed for ER-negative samples (n = 3) [32], and an approximate variance for a Pearson's correlation coefficient was used to derive its 95% confidence interval. To summarize ER-specific results from the individual studies, Fisher's Z transformation and its variance were used in pooling correlation from different studies. The weighted average of Fisher's Z transformation and its 95% confidence interval were first estimated based on a fixed-effect model, taking into account the variance associated with each study. The ER-specific pooled estimate of Pearson's correlation coefficient and its 95% confidence interval were then derived from the estimates based on the Fisher's Z transformation. We applied a random-effect model for meta-analysis [33] to evaluate whether levels of co-expressions between Notch-1, survivin, and keratin-5 differ between ER-negative and ER-positive samples among the different studies.
###end p 26
###begin title 27
Cells, reagents and transfections
###end title 27
###begin p 28
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
The breast adenocarcinoma MDA-MB-231 cell line was obtained from the American Type Culture Collection (Manassas, VA, USA), and was maintained in culture as recommended by the supplier. The cDNA encoding activated NIC was characterized previously [34]. MDA-MB-231 cells were transfected with control plasmid cDNA or NIC cDNA (2 mug) using 6 mul LipofectAmine (Invitrogen, Carlsbad, CA, USA) in Opti-Mem medium (1 ml) (Gibco, Carlsbad, CA, USA). The media was changed after 5 hours, and cells were harvested after 24 hours.
###end p 28
###begin p 29
###xml 148 150 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
The peptidyl gamma-secretase inhibitor z-Leu-Leu-Nle-CHO was purchased from Calbiochem (San Diego, CA, USA), and has been characterized previously [35]. For gene silencing experiments by siRNA, MDA-MB-231 cells were transfected with double-stranded RNA oligonucleotide directed to Notch-1 (pool of three siRNA; Santa Cruz, Santa Cruz, CA, USA), survivin, or control nontargeted sequences using 10 mul HiPerfect (Gibco). Cells under the various conditions were harvested after 48 hours, and were analyzed by western blotting.
###end p 29
###begin title 30
Results
###end title 30
###begin title 31
Expression of Notch-1 and survivin in basal breast cancer
###end title 31
###begin p 32
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 182 189 182 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 731 732 729 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 897 898 895 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
Recent studies have shown that Notch activation results in increased expression of survivin in basal breast cancer cell lines [35]. To determine whether a similar association occurs in vivo, we examined by immunohistochemistry a panel of basal breast cancer cases for expression of activated Notch-1 (NIC) and survivin. The average age of the nine patients was 52.3 +/- 6.1 years. All cases were grade 3 tumors with negative protein expression of ER, progesterone receptor, and HER-2, and positive protein expression of keratin 5/6, as assessed by immunohistochemistry. Activated Notch-1 was abundantly expressed in all cases examined of basal breast cancer, and was localized to both the cytosol and nuclei of tumor cells (Figure 1). Survivin was also strongly expressed in all basal breast cancer cases, and was similarly localized to the nuclei and cytosol of the tumor cell population (Figure 1).
###end p 32
###begin p 33
Expression of activated Notch-1 and survivin in basal breast cancer. Representative basal breast cancer cases were analyzed by immunohistochemistry. NIC, Notch-1 intracellular domain.
###end p 33
###begin title 34
Expression of Notch-1 mRNA in breast cancer microarray databases
###end title 34
###begin p 35
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 239 247 239 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 330 339 330 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5</italic>
###xml 341 351 341 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-14</italic>
###xml 357 360 357 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">kit</italic>
###xml 395 403 395 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 415 417 415 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 450 451 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 80 87 <span type="species:ncbi:9606">patient</span>
###xml 147 152 <span type="species:ncbi:9606">human</span>
We next analyzed the expression of Notch-1 mRNA in an established breast cancer patient cohort. Supervised hierarchical clustering of 232 cases of human breast cancer [25], using intrinsic gene analysis, revealed that higher expression of Notch-1 segregated with basal breast cancer. Other known markers of the disease, including keratin-5, keratin-14, and kit, were also highly correlated with Notch-1 expression (r >/= 0.58) in this cohort (Figure 2).
###end p 35
###begin p 36
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
Notch-1 segregates with basal breast cancer. Heat map of 232 cases of breast cancer. Unclassified, gray; normal breast-like, green; luminal A, light blue; luminal B, dark blue; HER-2+/estrogen receptor-negative (ER-), purple; basal, red.
###end p 36
###begin p 37
###xml 137 145 137 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 148 150 148 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 205 213 205 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 353 355 353 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 615 617 615 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 656 664 656 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 746 748 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
###xml 541 549 <span type="species:ncbi:9606">patients</span>
One hundred and twenty-five patients with associated clinical outcome data were further analyzed. When stratified according to levels of Notch-1 log2 transcript ratios, tumors with the highest quartile of Notch-1 gene expression (first quartile) exhibited abbreviated overall survival with a median survival of 27 months compared with the other groups (P < 0.001 via the log-rank test) (Figure 3a). Seventy-two percent of tumors in this first quartile (23/32 tumors) were classified as basal breast cancer, and the overall survival of these patients was approximately 50% lower of that of the remaining population (P < 0.02). Conversely, reduced levels of Notch-1 (second to fourth quartiles) were associated with better overall survival (Figure 3a). The percentage of basal breast cancers in these groups was 17% (second quartile, 5/30 tumors), 20% (third quartile, 6/30 tumors), and 10% (fourth quartile, 3/31 tumors), respectively.
###end p 37
###begin p 38
###xml 18 22 18 22 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 154 158 154 158 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 178 182 178 182 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
Overall survival. (a) Kaplan-Meier curves of differential overall survival were plotted according to Notch-1 expression in the entire cohort (quartiles). (b) Nonbasal tumors and (c) basal tumors were subgrouped into high Notch-1 expression (fourth quartile) or low Notch-1 expression (first to third quartiles) and were analyzed for overall survival.
###end p 38
###begin p 39
###xml 164 172 164 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 241 243 241 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 279 287 279 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 390 398 390 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 529 537 529 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
The tumors were then segregated based on basal or nonbasal subgroup status and were analyzed for overall survival. In the nonbasal breast tumors, the expression of Notch-1 was not associated with significant differences in overall survival (P = 0.2734) (Figure 3b). In contrast, Notch-1 levels dictated overall survival in basal breast tumors (Figure 3c). In this basal subgroup, increased Notch-1 expression (fourth quartile) greatly reduced overall survival to the median of 26 months (Figure 3c). Comparatively, low levels of Notch-1 (first to third quartiles) demonstrated improved overall survival (Figure 3c).
###end p 39
###begin title 40
Gene expression correlation in basal breast cancer
###end title 40
###begin p 41
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 235 244 235 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin </italic>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 371 372 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 380 390 380 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5 </italic>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
We next carried out a meta-analysis of published microarray datasets to identify genes associated with Notch and potentially implicated in the molecular pathogenesis of basal breast cancer. Based on our recent data [35], we focused on survivin - a mitotic regulator and cell death inhibitor overexpressed in breast cancer [3,21], and associated with unfavorable outcome [2] - and keratin-5 - a marker of basal epithelium, often linked to a progenitor/stem cell phenotype [13].
###end p 41
###begin p 42
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 509 519 509 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5 </italic>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 594 602 594 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 606 615 606 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin </italic>
###xml 640 650 640 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5 </italic>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 667 668 667 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 736 743 736 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1</italic>
###xml 745 753 745 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 759 769 759 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5 </italic>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
Fifteen microarray datasets, mostly employing Affymetrix technology, published between 2002 and 2007 met the search criteria (Table 1). The overall median age of patients was 55.2 years. The breast tumors examined were typically < 5 cm, encompassing all grades, and included lymph node-positive and lymph node-negative disease. In one study, separate databases for lobular and ductal breast cancer were examined [36] - bringing the datasets analyzed to a total of 16. Two studies did not contain downloadable keratin-5 expression data [36,37], and one study contained 68 out of 96 samples with Notch-1 and survivin data and 19 samples with keratin-5 data [38]. Table 2 presents the descriptive statistics of each cohort with respect to Notch-1, survivin, and keratin-5 relative expression.
###end p 42
###begin p 43
Descriptive statistics of studies in the meta-analysis
###end p 43
###begin p 44
###xml 40 42 40 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 159 166 159 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1</italic>
###xml 168 176 168 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 182 192 182 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5 </italic>
###xml 229 230 229 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 271 281 271 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5 </italic>
Mean, standard error of mean (SEM), and P value between estrogen receptor-negative (ER-) and estrogen receptor-positive (ER+) breast cancers are presented for Notch-1, survivin, and keratin-5 expression in the analyzed datasets. aUppsala cohort. * Subset of samples with keratin-5 data.
###end p 44
###begin title 45
A novel dual-gene signature in basal breast cancer
###end title 45
###begin p 46
###xml 87 97 87 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5 </italic>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 190 198 190 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 341 348 341 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1</italic>
###xml 349 359 349 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5 </italic>
###xml 444 446 444 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 478 487 478 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin </italic>
###xml 491 501 491 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5 </italic>
###xml 691 693 691 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 754 763 754 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin </italic>
###xml 767 777 767 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5 </italic>
###xml 955 957 955 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Analysis of 507 ER-negative and 1,356 ER-positive breast cancer patients revealed that keratin-5 associated with ER-negative breast cancers (Figure 4a) in seven out of 13 datasets, and that Notch-1 associated with ER-negative breast cancers in nine out of 16 datasets (Table 2). Pooled estimates of Pearson's correlation coefficient between Notch-1/keratin-5 were 0.3315 and 0.2043 for ER-negative and ER-positive breast cancers, respectively (P = 0.04) (Figure 4a). Similarly, survivin and keratin-5 co-segregated in ER-negative breast cancer, with a pooled estimate of Pearson's correlation coefficient of 0.1314 for ER-negative breast cancer and of -0.2408 for ER-positive breast cancer (P < 0.0001) (Figure 4b). A negative correlation exists between survivin and keratin-5 in ER-positive breast cancers most probably because other transcriptional and nontranscriptional mechanisms are likely to control survivin expression in nonbasal cancers (Figure 4b).
###end p 46
###begin p 47
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1</italic>
###xml 27 35 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 41 51 41 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5 </italic>
###xml 193 197 193 197 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 197 204 197 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1</italic>
###xml 205 214 205 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5</italic>
###xml 216 220 216 220 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 220 228 220 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Survivin</italic>
###xml 229 238 229 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5</italic>
###xml 240 244 240 244 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 244 260 244 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1/survivin</italic>
Co-segregation of Notch-1, survivin, and keratin-5 in breast cancer. Pearson's correlation coefficient and the 95% confidence interval were calculated from the analysis of individual datasets. (a) Notch-1/keratin-5. (b) Survivin/keratin-5. (c) Notch-1/survivin. For study details, see Table 2. ER, estrogen receptor.
###end p 47
###begin p 48
###xml 87 96 87 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin </italic>
###xml 143 145 143 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 184 185 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 235 243 235 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1 </italic>
###xml 247 256 247 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin </italic>
###xml 342 344 342 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Analysis of 604 ER-negative and 1,463 ER-positive breast cancer patients revealed that survivin segregated with ER-negative tumors (two-tailed P < 0.05) in 12 out of 16 cohorts (Table 2). The Pearson's correlation coefficients between Notch-1 and survivin were 0.1804 and -0.0674 for ER-negative and ER-positive breast cancers, respectively (P < 0.0001) (Figure 4c).
###end p 48
###begin title 49
Notch-1 regulation of survivin expression
###end title 49
###begin p 50
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 634 643 630 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin </italic>
###xml 781 783 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
Consistent with the model presented above, recent studies have shown that survivin may function as a direct transcriptional target of Notch-1, thus controlling mitotic transition and resistance to apoptosis in breast cancer [35]. In agreement with these data, transfection of ER-negative breast cancer MDA-MB-231 cells with NIC resulted in increased survivin expression, as determined by western blotting, whereas acute siRNA silencing of Notch was associated with reduced survivin levels and induction of apoptosis (data not shown). Similarly, inhibition of Notch signaling by a pharmacologic inhibitor of gamma-secretase suppressed survivin gene expression (data not shown), validating the identity of survivin as a direct transcriptional target of Notch in breast cancer cells [35].
###end p 50
###begin title 51
Discussion
###end title 51
###begin p 52
###xml 266 273 266 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Notch-1</italic>
###xml 275 283 275 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin</italic>
###xml 289 299 289 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">keratin-5 </italic>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 375 383 <span type="species:ncbi:9606">patients</span>
In the present study, we have shown that Notch-1 is preferentially expressed in breast cancer, as compared with normal tissues, segregates with basal disease, and correlates with abbreviated survival. In a meta-analysis of multiple, independent microarray datasets, Notch-1, survivin, and keratin-5 selectively co-associated with ER-negative versus ER-positive breast cancer patients. Consistent with recent observations [35], survivin was validated as a direct transcriptional target of Notch in model ER-negative breast cancer cells.
###end p 52
###begin p 53
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 852 854 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
These findings add to an in-depth molecular classification of breast cancer [4] - and in particular basal breast cancer, a disease variant that still poses significant therapeutic challenges. In addition to high-risk genetics [7,8] and aggressive histologic features [5], it has been speculated that basal breast cancer may originate from a progenitor/stem cell compartment in the basal mammary epithelium. This is consistent with a proposed role for Notch in mammary progenitor cell differentiation and maintenance [39], and potentially in the early events of their transformation [40]. Such a pathway may not be exclusively limited to breast cancer [20], given that deregulated Notch signaling has been implicated as a driver of disparate malignancies [15], as promoting aberrant cell cycle progression [41], and associated with unfavorable outcome [18].
###end p 53
###begin p 54
###xml 79 86 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">direct </italic>
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 247 256 243 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin </italic>
###xml 467 469 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
In this context, survivin appears ideally suited to function as a pleiotropic, direct Notch effector gene in clinically aggressive breast cancer [2]. At the molecular level, this involves occupancy of discrete RPB-Jkappa binding element(s) in the survivin promoter upon Notch activation, which results in transcriptional upregulation of survivin levels, inhibition of apoptosis, and acceleration of mitotic transitions selectively in ER-negative breast cancer cells [35]. Whether deregulation of a Notch-survivin signaling axis is preferentially operative in a progenitor/stem cell compartment is currently not known.
###end p 54
###begin p 55
###xml 234 236 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 343 345 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 358 360 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 373 375 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 615 617 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 726 735 723 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">survivin </italic>
###xml 810 812 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 888 890 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 959 961 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1063 1065 1060 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1092 1094 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 658 663 <span type="species:ncbi:9606">human</span>
Intriguing, however, is that another developmental gene expression pathway (that is, Wnt/beta-catenin) has been implicated in controlling survivin levels in intestinal crypt progenitor cells, potentially contributing to colon cancer [42], and that survivin expression been consistently associated with stemness gene signatures of mesenchymal [43], neuronal [44], and skin [45] progenitor cells. Results of conditional knockout studies appear to support this model, as heterozygous deletion of survivin produced complete bone marrow ablation, loss of hematopoietic progenitor/stem cells, and rapid animal mortality [22]. This pathway may have a clear link to human disease, as lineage-specific methylation and silencing of the survivin gene has been linked to bone marrow depletion in myelodsyplastic syndrome [46]. With respect to breast cancer, Notch-dependent upregulation of survivin [35] may broadly suppress apoptosis, deregulate cell cycle progression [21], and ultimately promote resistance to mainstay therapeutic agents in this disease, such as taxanes [47] and DNA damaging agents [48].
###end p 55
###begin p 56
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 649 651 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 687 689 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 726 728 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 868 870 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1005 1012 993 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1119 1121 1107 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1278 1280 1266 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
###xml 447 455 <span type="species:ncbi:9606">patients</span>
###xml 818 826 <span type="species:ncbi:9606">patients</span>
###xml 1204 1211 <span type="species:ncbi:9606">patient</span>
Although the diagnosis of triple-negative, basal breast cancer is straightforward [6], these patients continue to pose therapeutic challenges for the aggressive nature of the disease, which is prone to relapse, and the lack of appropriate, molecularly targeted agents [10]. Based on the findings presented herein, it may be possible to envision antagonists of Notch [49] and of survivin [21] as potential molecular therapy for basal breast cancer patients. Agents that interfere with Notch signaling inhibit the enzyme gamma-secretase, which is responsible for the activating intracellular cleavage of Notch upon ligand binding at the cell surface [15]. Despite concerns of specificity [50] and potential intestinal toxicity [51], gamma-secretase inhibitor molecules are being tested as molecular therapy for leukemic patients harboring activating mutations in Notch [49]. In our recent studies, systemic administration of a peptidyl gamma-secretase inhibitor significantly inhibited breast cancer growth in vivo, and almost completely abolished metastatic dissemination, with no detectable organ or systemic toxicity [35]. Antagonists of survivin are also available in the clinic, producing encouraging patient responses and manageable toxicity in early-phase clinical trials [21].
###end p 56
###begin p 57
###xml 36 45 36 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 145 152 145 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 426 433 426 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 703 711 703 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 828 830 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 811 818 <span type="species:ncbi:9606">patient</span>
###xml 932 940 <span type="species:ncbi:9606">patients</span>
In summary, we have extended recent in vitro observations [35] and have validated the existence of a functional Notch-1/survivin signaling axis, in vivo, selectively in patients with basal breast cancer. Targeting Notch-1 signaling in model breast cancer cells lowered survivin levels, resulting in pronounced anti-tumor effects [35]. Taken together with the stringent correlation reported here across disparate tumor series, in vivo, this observation raises the possibility that basal breast cancer cells may selectively become dependent on, or addicted to, Notch/survivin signaling for their maintenance [52]. Although it is unclear to what extent oncogene addiction maintains the malignant phenotype in vivo [53], antagonists of such pathways have produced impressive clinical responses, at least in certain patient subsets [54]. A similar rationale may be envisioned here for targeting Notch and survivin in basal breast cancer patients, especially if this pathway can be disabled in a progenitor/stem cell compartment, acting as a potential disease reservoir contributing to a high incidence of relapses.
###end p 57
###begin title 58
Conclusion
###end title 58
###begin p 59
Expression of Notch-1 and survivin segregates with clinically aggressive and recurrence-prone basal breast cancer. Antagonists of these signaling pathways may be considered as targeted, novel molecular therapy of basal breast cancer.
###end p 59
###begin title 60
Abbreviations
###end title 60
###begin p 61
###xml 30 35 <span type="species:ncbi:9606">human</span>
ER: estrogen receptor; HER-2: human epidermal growth factor receptor 2; NIC: Notch-1 intracellular domain; PBS: phosphate-buffered saline; siRNA: small interfering RNA.
###end p 61
###begin title 62
Competing interests
###end title 62
###begin p 63
The authors declare that they have no competing interests.
###end p 63
###begin title 64
Authors' contributions
###end title 64
###begin p 65
###xml 382 387 <span type="species:ncbi:9606">human</span>
CWL, JP, and MG carried out experiments of survivin and Notch expression and function in breast cancer as well as immunohistochemical analysis in primary normal and tumor samples. KS performed the hierarchical clustering experiments. QL and C-CH provided statistical evaluation and interpretation of the microarray and Pearson analysis data. AK analyzed the immunohistochemistry of human breast tumor samples and provided clinical and pathological data. DCA participated in the design and coordination of the study. CWL and DCA wrote the paper. All authors read and approved the final manuscript.
###end p 65
###begin title 66
Acknowledgements
###end title 66
###begin p 67
The present work is supported by grants from the National Institutes of Health: CA132622 (CWL), and HL54131, CA90917, and CA78810 (DCA).
###end p 67
###begin article-title 68
The prognostic role of a gene signature from tumorigenic breast-cancer cells
###end article-title 68
###begin article-title 69
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
###end article-title 69
###begin article-title 70
Gene expression profiling predicts clinical outcome of breast cancer
###end article-title 70
###begin article-title 71
###xml 98 105 <span type="species:ncbi:9606">patient</span>
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
###end article-title 71
###begin article-title 72
Demystifying basal-like breast carcinomas
###end article-title 72
###begin article-title 73
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
###end article-title 73
###begin article-title 74
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular portraits of human breast tumours
###end article-title 74
###begin article-title 75
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
###end article-title 75
###begin article-title 76
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
###end article-title 76
###begin article-title 77
Triple-negative breast cancer: therapeutic options
###end article-title 77
###begin article-title 78
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
###end article-title 78
###begin article-title 79
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
###end article-title 79
###begin article-title 80
Breast cancer, stem/progenitor cells and the estrogen receptor
###end article-title 80
###begin article-title 81
Wnt/beta-catenin signaling in development and disease
###end article-title 81
###begin article-title 82
Notch signalling: a simple pathway becomes complex
###end article-title 82
###begin article-title 83
The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy
###end article-title 83
###begin article-title 84
###xml 54 59 <span type="species:ncbi:9606">human</span>
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland
###end article-title 84
###begin article-title 85
###xml 58 63 <span type="species:ncbi:9606">human</span>
High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival
###end article-title 85
###begin article-title 86
Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
###end article-title 86
###begin article-title 87
###xml 42 47 <span type="species:ncbi:9606">human</span>
Aberrant activation of notch signaling in human breast cancer
###end article-title 87
###begin article-title 88
Survivin, cancer networks and pathway-directed drug discovery
###end article-title 88
###begin article-title 89
Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells
###end article-title 89
###begin article-title 90
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis
###end article-title 90
###begin article-title 91
University of North Carolina Microarray Database
###end article-title 91
###begin article-title 92
###xml 61 67 <span type="species:ncbi:10090">murine</span>
###xml 97 102 <span type="species:ncbi:9606">human</span>
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
###end article-title 92
###begin article-title 93
Cluster analysis and display of genome-wide expression patterns
###end article-title 93
###begin article-title 94
Java Treeview - extensible visualization of microarray data
###end article-title 94
###begin article-title 95
SAS Institute JMP Software
###end article-title 95
###begin article-title 96
Oncomine
###end article-title 96
###begin article-title 97
ONCOMINE: a cancer microarray database and integrated data-mining platform
###end article-title 97
###begin article-title 98
Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis
###end article-title 98
###begin article-title 99
Meta-analysis in clinical trials
###end article-title 99
###begin article-title 100
Mitosis-independent survivin gene expression in vivo and regulation by p53
###end article-title 100
###begin article-title 101
Molecular Dependence of Estrogen Receptor-Negative Breast Cancer on a Notch-Survivin Signaling Axis
###end article-title 101
###begin article-title 102
Different gene expression patterns in invasive lobular and ductal carcinomas of the breast
###end article-title 102
###begin article-title 103
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
###end article-title 103
###begin article-title 104
A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors
###end article-title 104
###begin article-title 105
###xml 37 42 <span type="species:ncbi:9606">human</span>
Transcriptome analysis of the normal human mammary cell commitment and differentiation process
###end article-title 105
###begin article-title 106
Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways
###end article-title 106
###begin article-title 107
Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic)
###end article-title 107
###begin article-title 108
Survivin and molecular pathogenesis of colorectal cancer
###end article-title 108
###begin article-title 109
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients
###end article-title 109
###begin article-title 110
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
Purification of neuronal precursors from the adult mouse brain: comprehensive gene expression analysis provides new insights into the control of cell migration, differentiation, and homeostasis
###end article-title 110
###begin article-title 111
Survivin identifies keratinocyte stem cells and it is down-regulated by anti-{beta}1 integrin during anoikis
###end article-title 111
###begin article-title 112
DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation
###end article-title 112
###begin article-title 113
A p34(cdc2) survival checkpoint in cancer
###end article-title 113
###begin article-title 114
Activated checkpoint kinase 2 provides a survival signal for tumor cells
###end article-title 114
###begin article-title 115
Notch signaling, gamma-secretase inhibitors, and cancer therapy
###end article-title 115
###begin article-title 116
Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling
###end article-title 116
###begin article-title 117
Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation
###end article-title 117
###begin article-title 118
Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy
###end article-title 118
###begin article-title 119
Oncogene addiction; Sometimes a temporary slavery
###end article-title 119
###begin article-title 120
Epidermal growth factor receptor mutations in lung cancer
###end article-title 120
###begin article-title 121
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
###end article-title 121
###begin article-title 122
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
###end article-title 122
###begin article-title 123
Prognosis and gene expression profiling of 20q13-amplified breast cancers
###end article-title 123
###begin article-title 124
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
###end article-title 124
###begin article-title 125
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer
###end article-title 125
###begin article-title 126
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 117 124 <span type="species:ncbi:9606">patient</span>
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
###end article-title 126
###begin article-title 127
Genes that mediate breast cancer metastasis to lung
###end article-title 127
###begin article-title 128
###xml 42 47 <span type="species:ncbi:9606">human</span>
X chromosomal abnormalities in basal-like human breast cancer
###end article-title 128
###begin article-title 129
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
###end article-title 129
###begin article-title 130
A gene-expression signature as a predictor of survival in breast cancer
###end article-title 130
###begin article-title 131
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
###end article-title 131

